gov), and

ISRCTN13643354.

Findings 2029 patients were randomly allocated to treatment groups (1017 candesartan, 1012 Vismodegib solubility dmso placebo), and data for status at 6 months were available for 2004 patients (99%; 1000 candesartan, 1004 placebo). During the 7-day treatment period, blood pressures were significantly lower in patients allocated candesartan than in those on placebo (mean 147/82 mm Hg [SD 23/14] in the candesartan group on day 7 vs 152/84 mm Hg [22/14] in the placebo group; p<0.0001). During 6 months’ follow-up, the risk of the composite vascular endpoint did not differ between treatment groups (candesartan, 120 events, vs placebo, 111 events; adjusted hazard ratio 1.09, 95% CI 0.84-1.41; p=0.52). Analysis of functional

outcome suggested a higher risk of poor outcome in the candesartan GSK872 mw group (adjusted common odds ratio 1.17, 95% CI 100-138; p=0.048 [not significant at p <= 0.025 level]). The observed effects were similar for all prespecified secondary endpoints (including death from any cause, vascular death, ischaemic stroke, haemorrhagic stroke, myocardial infarction, stroke progression, symptomatic hypotension, and renal failure) and outcomes (Scandinavian Stroke Scale score at 7 days and Barthel index at 6 months), and there was no evidence of a differential effect in any of the prespecified subgroups. During follow-up, nine (1%) patients on candesartan and five (<1%) on placebo had symptomatic hypotension, and renal failure was reported for 18 (2%) patients taking candesartan and 13 (1%) allocated placebo.

Interpretation There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure. If anything, the evidence suggested a harmful effect.”
“We investigated the crossmodal temporal discrimination deficit characterizing older adults and its event-related potential (electroencephalogram) correlates using an audiovisual temporal order judgment

task. Audiovisual stimuli were presented at stimulus onset asynchronies (SOA) of 70 or 270 ms. Older were less accurate than younger adults ADAMTS5 with an SOA of 270ms but not 70 ms. With an SOA of 270ms only, older adults had smaller posterior P1 and frontocentral N1 amplitudes for visual stimuli in auditory-visual trials and auditory stimuli in visual-auditory trials, respectively. These results suggest a deficit in cross-sensory processing with aging reflected at the behavioural and neural level, and suggest an impairment in switching between modalities even when the inputs are separated by long temporal intervals. NeuroReport 22:554-558 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.”
“Background The use of cell-culture technologies for the manufacture of influenza vaccines might contribute to improved strain selection and robust vaccine supplies.